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LOWER RESPIRATORY TRACT INFECTION CAUSED
BY RESPIRATORY SYNCYTIAL VIRUS IN INFANTS:
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INTRODUCTION: Respiratory syncytial virus (RSV) is a major etiological agent of lower respiratory tract infection in infants.
Genotypes of this virus and the role of the infants’ serum antibodies have yet to be fully clarified. This knowledge is important for
the development of effective therapeutic and prophylactic measures.
OBJECTIVES: To evaluate the types and genotypes of RSV causing respiratory tract infection in infants, to analyze the association
of subtype-specific serum antibodies with the occurrence of infection and to evaluate the presence of subtype-specific antibodies in
the infants’ mothers and their association with the profile of the childrens’ serum antibodies.
METHODS: This was a prospective study on infants hospitalized with respiratory infection. Nasopharyngeal secretions were
collected for viral investigation using indirect immunofluorescence and viral culture and blood was collected to test for antibodies
using the Luminex Multiplex system. RESULTS: 192 infants were evaluated, with 60.9% having RSV (73.5%- A and 20.5% B).
Six genotypes of the virus were identified: A5, A2, B3, B5, A7 and B4. The seroprevalence of the subtype-specific serum antibodies
was high. The presence and levels of subtype-specific antibodies were similar, irrespective of the presence of infection or the viral
type or genotype. The mothers’ antibody profiles were similar to their infants’.
CONCLUSIONS: Although the prevalence of subtype-specific antibodies was elevated, these antibodies did not provide protection
independently of virus type/genotype. The similarity in the profiles of subtype-specific antibodies presented by the mothers and their
children was consistent with transplacental passage.
KEY WORDS: Respiratory. Syncytial. Antibody. Immunity. Infant.
INTRODUCTION
Respiratory Syncytial Virus (RSV) is a major cause of
respiratory infection in infants.1 During the RSV season,
it is estimated that about 40% of children will develop a
lower respiratory tract infection (LRTI).2-5 Changes in air-
way immunity and/or integrity seem to play a role in the
pathogenesis of this infection, as may be observed in vul-
nerable groups, such as neonates, premature infants and
those with congenital or acquired immunodeficiencies or
cardiac or respiratory conditions.5-7 However, approximately
70% of the infants hospitalized due to RSV-LRTI do not
present these risk factors,6 therefore indicating the poten-
tial involvement of other variables. One important aspect
is the role of serum antibodies, as RSV-LRTI primarily af-
fects children in their first months of life, when their se-
rum level of maternal anti-RSV antibodies is high. It is pos-
sible, however, to provide adequate protection against RSV-
LTRI with the prophylactic use of immunoglobulins (RSV-
Ig) or monoclonal antibodies in infants.8-11 A reasonable ex-
planation would be the lack of specificity of the maternal
antibodies to the RSV genotype (subtype) infecting the in-
fant, due to the known fact that circulating genotypes of
710
CLINICS 2007;62(6):709-16Lower respiratory tract infection caused by respiratory syncytial virus in infants
Vieira SE et al.
RSV in a current season are substituted for others a few
years later; therefore, the serum maternal antibodies at the
time of infection would not correspond to the current in-
fecting genotype, but rather to genotypes from previous
years.12,13 In order to test this hypothesis, the authors iden-
tified the type/genotype of the RSV detected in infants with
LRTI, and evaluated the presence and amount of serum
subtype-specific antibodies for the RSV genotype responsi-
ble for the infection. Additionally, anti-RSV antibodies were
measured in the sera of the mothers of infants with LRTI.
This knowledge will hopefully contribute to the devel-
opment of prophylactic measures, including active immu-
nization.
SAMPLES AND METHODS
This prospective study was approved by the Ethics and
Research Committees of the University Hospital of the
Universidade de São Paulo. Parents or legal guardians
signed the Informed Consent.
From March 1999 to June 2000, infants admitted at the
University Hospital were selected according to the follow-
ing inclusion criteria: younger than one year of age, dura-
tion of the respiratory condition of seven days or less, LRTI
diagnosis at admission, and hospitalization between Mon-
day to Thursday (due to operational reasons). LRTI was de-
termined by clinical parameters, which consisted of one or
more of the following findings: snores, wheezing and crack-
les, and by radiological parameters, which in turn consisted
of one or more of the following findings: diffuse pulmo-
nary hyperinflation, alveolar condensation, and pulmonary
interstitial infiltration.3,14 The main exclusion criterion was
an inconclusive result in the immunofluorescence assay,
defined as a fluorescence pattern distributed randomly on
the slide, but lacking the characteristic appearance of RSV.
Two hundred and three patients met the inclusion cri-
teria and 11 were excluded. The sample of 192 patients was
distributed into two groups: infants infected with RSV
(RSV+), and infants with negative findings for RSV (RSV-),
the last being considered the control group. Table 1 shows
the demographics of the sample.
Selected patients were submitted to collection of respira-
tory secretions by means of a nasal swab in one nare and by
nasopharyngeal aspirate in the other nare. 15 Material was
collected within the first 24 hours after hospital admission.
A three milliliter blood sample was drawn from all pa-
tients within the first 48 hours of hospitalization for analysis
of RSV-specific serum antibodies. Biological mothers who
were at the hospital in the first 48 hours after the admis-
sion of their infants also had a sample drawn to undergo
the same analysis.
Laboratorial processing of respiratory secretion samples
Clinical laboratory tests were performed at the Virol-
ogy Laboratory of the Center for Disease Control in At-
lanta, GA, USA, for determination of RSV genotype and
specific antibodies, and at the XXX Virology Laboratory
of Instituto de Ciências Biomédicas in São Paulo, SP, Bra-
zil, for viral isolation.
The media containing the swab and aspirate materials
were homogenized and the samples were separated into
aliquots for inoculation into cell cultures, indirect immun-
ofluorescence and storage. The cell culture media utilized
were Hep2, Hela-1 and NCI-H292. Indirect immunofluo-
rescence was performed both directly on the collected ma-
terial and on the culture-seeded material. Indirect immun-
ofluorescence assay tests and specific monoclonal antibod-
ies for RSV, influenza viruses A and B, parainfluenza vi-
ruses 1, 2 and 3 and adenovirus were used, according to
pre-established techniques (Chemicon International® com-
mercial kit). Two specific monoclonal antibodies were used
for identifying the epitopes of the RSV isolates: Mab 92 –
11 for type A, and Mab 102-10b for type B.
Genotyping of RSV isolates
Viral RNA was extracted using guanidinium-isothio-
cyanate-phenol (RNAzol; Teltest, FriendswoodR,TX). RNA
was annealed with 20 mM F1 primer and reverse-tran-
scribed with avian myeloblastosis virus reverse transcriptase
(Boehringer Mannheim). The PCR assay was carried out
following cDNA synthesis. The cDNA resulting from this
process was submitted to two PCR reactions in order to
Table 1 - Demographic characteristics and diagnosis status
of the RSV positive and negative groups.
Characteristic RSV + RSV - Total p
117 cases 75 cases 192 cases
Mean age +/- SD 4.7 +/- 4.3 5.6 +/- 3.7 5.0 (4.1) 0.13
(months)
N (%) N (%) N (%)
Gender
Male 65 (55.6) 38 (50.7) 107 (55.7) 0.51
Female 52 (44.4) 37 (49.3) 85 (44.3)
Well-Developed* 88 (75.2) 53 (70.7) 141 (73.4) 0.49
Diagnosis
Bronchiolitis 57 (48.7) 18 (24.0) 75 (39.1) 0.01
Pneumonia 18 (15.4) 30 (40.0) 48 (25.0) 0.04
Bronchiolitis and 16 (13.7) 6 (8.0) 22 (11.5) 0.23
pneumonia
Wheezing 8 (6.8 ) 8 (10,7) 16 (8,3) 0,35
Wheezing and 18 (15.4) 13 (17.3) 31 (16.1) 0.72
pneumonia
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amplify distinct genes: gene F, without significant variabil-
ity, and gene G, which allows for the classification of the
viral genotypes due to its gene sequence variability.12,16,17
Phylogenetic Analysis
The products obtained from RSV genome sequencing
were submitted to the Molecular Evolutionary Genetics
Analysis (MEGA) program version 1.02, which analyzes
similarities and calculates the genetic distance among se-
quences, and also to phylogenetic analysis using parsimony
and other methods (Phylogenetic Analysis Using Parsi-
mony* Program - version 4.0 Beta - Sinauer Associates,
Inc.), an instrument for inference and analysis of
phylogenetic trees based on the methods of parsimony and
genetic distance.12,16
Identification of specific subtype antibodies in serum
samples
The anti-RSV antibodies studied were: anti-A1, anti-A2,
anti-A3, anti-A4, anti-A5, anti-A6, anti-A7, anti-B1, anti-
B4 and anti-B. The Luminex Multiplex System (Austin, TX)
was used to identify specific subtype antibodies for the g1
and g2 regions of the RSV G protein. This method consists
of mixing the patient’s blood sample with a solution con-
taining specific RSV genotype antigens coupled to
microspheres. The identification of antigen-bound antibody
was carried out using another biotin-labeled and streptavidin-
fluorescein-tagged antibody, Readings were performed with
FACScan, which provides the average sample fluorescence.
In order to detect the presence of each subtype-specific anti-
body in the serum, the fluorescence index (FI) was used.
Jones et al have previously described this method based on
analysis of sample fluorescence in comparison to negative
controls. The FI is considered positive if it is equal to or
greater than 3.18
STATISTICAL ANALYSIS
Means and ratios were used to evaluate demographic
and clinical variables. The Student’s t test was applied to
compare means, the Chi-square and Fisher’s exact tests
were used to examine relationships among variables, the
homogeneity Chi-square test was used to compare
seroprevalence, and one-way analysis of variance (ANOVA)
was used to determine the association between the amount
of antibodies and the occurrence of infection. In order to
correct for the distortion observed due to the obtained re-
sults’ amplitudes, FIs were transformed into natural loga-
rithms (log FI) and their means were compared. Poisson
regression was applied to evaluate the correlation between
the antibody means and the occurrence of infections, logistic
regression was used to determine the cutoff point of the lev-
els of anti-A2 and anti-A5 antibodies, and Spearman’s co-
efficient was used to study the correlation between the
prevalence of antibody in the infants and in their mothers.
The significance level was set at 5% and the confidence
intervals were set at 95%. The statistical software packages
Excel 2000, SAS 8.0 and SPSS 10.0 were utilized.19,20
RESULTS
The RSV(+) group consisted of 117 infants, of which
86 (73.5%) had RSV A and 24 (20.5%) had RSV B. The
RSV type was not identified in seven (6%) patients. The
genotypes identified in 71 positive samples were: GA5 (28
samples), GA2 (21 samples), GA7 (one sample), GB3 (17
samples), GB5 (three samples), and GB4 (one sample). In
the RSV(-) group, which included 75 infants, influenza A
(two samples) and adenovirus (one sample) were identified.
In 172 (89.6%) infants, some subtype-specific antibod-
ies against antigen A were identified, while in 153 infants
(79.7%) some subtype-specific antibodies against antigen
B were identified. The subtype-specific antibodies anti-A2,
anti-A1 and anti-A5 were the most prevalent (80.7%,
56.2%, and 44.8%, respectively). The prevalence of the
other antibody subtypes were: anti A3 – 8.8%, anti A4 –
13.5%, anti A6 – 11.5%, anti A7- 11.5%, anti B1 – 17.1%
and anti B4 – 20.3%. The majority of the anti-B antibod-
ies were not subject to subtype categorization (75%).
The seroprevalences of anti-A and anti-B antibodies in
infants with RSV A and RSV B infections, and also in the
RSV(-) group, were similar. Likewise, the seroprevalences
of subtype-specific antibodies were similar in these three
groups (Table 2).
The prevalence of subtype-specific antibodies evaluated
in children infected by the RSV genotypes GA2, GA5 and
GB3 and in those belonging to the RSV (-) group were all
similar. In addition, the Anti-2 and Anti-5 subtype-specific
antibodies were found in children infected by the GA2 and
GA5 RSV genotypes (Table 3).
The amount of serum subtype-specific antibodies to RSV
(means of log FI) in infants infected with RSV A, RSV B
and in the RSV(-) group were found to be similar between
the three groups. Similar results were obtained in analysis
for the RSV genotype A2-, A5- and B3-infected groups, as
well as for the RSV (-) group (Table 4).
Logistic regression was applied to examine the poten-
tial existence of a serum level of antibodies against the RSV
genotypes A2 and A5 that would be sufficient to protect in-
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Table 4 - Estimates of the amounts of anti-RSV subtype-specific antibodies in the sera of infants with RSV GA2, GA5,
GB3 and in the RSV(-) group.
ANTIBODIES FI# - VSR A2 FI# - VSR A5 FI# - VSR B3 FI# - RSV (-) P*
Med (IQI) Med (IQI) Med (IQI) Med (IQI)
Anti A1 3.6 (1.1-6.2) 2.6 (1.7-4.7) 4.0 (2.0-6.0) 3.5 (1.9-5.5) 0.81
Anti A2 6.6 (2.6-10.1) 5.6 (3.3-8.7) 8.3 (4.3-9.9) 6.9 (3.7-12.9) 0.61
Anti A3 0.7 (0.1-1-3) 0.4 (0.2-0.7) 0.3 (0.2-0.6) 0.3 (0.1-0.9) 0.61
Anti A4 0.5 (0.2-1.4) 0.7 (0.2-1-5) 0.7 (0.5-1.7) 0.6 (0.3-1.4) 0.81
Anti A5 1.6 (0.8-4.0) 3.2 (1.0-6.1) 4.1 (1.9-5-9) 2.9 (1.1-6.0) 0.61
Anti A6 0.3 (0.1-0.6) 0.2 (0.1-0.4) 0.2 (0.1-0.4) 0.2 (0.1-1.0) 0.44
Anti A7 0.3 (0.2-0.8) 0.4 (0.3-0.9) 0.5 (0.3-1-4) 0.5 (0.2-1.7) 0.93
Anti B1 0.5 (0.4-1.3) 1.0 (0.7-3.0) 0.8 (0.5-2.7) 0.8 (0.4-2.0) 0.37
Anti B4 0.4 (0.2-1.4) 0.8 (0.2-3.3) 0.5 (0.3-1.0) 0.5 (0.2-2.3) 0.57
Anti B n.cat ** 5.9 (2.1-16.8) 13.0(4.4-25.7) 7.7 (4.4-14.2) 7.9 (3.2-22.3) 0.50
# FI
= Fluorescence Index Med=median IQI =Interquartile interval (0.25-0.75)
*P of the mean of the natural log of the FI **n.cat. = not categorized
Table 3 - Prevalence of anti-RSV subtype-specific antibodies in the sera of infants infected with the most frequently found
RSV genotypes.
RSV genotype
Anti-RSV subtype-specific A2 A5 B3 RSV(-) P
antibodies* N=21 N=28 N=17 N=75
N (%) N (%) N (%) N (%)
Anti A1 12 (57.1) 14 (50.0) 12 (70.5) 45 (60.0) 0.59
Anti A2 15 (71.4) 24 (85.7) 14 (82.3) 66 (88.0) 0.32
Anti A3 03 (14.2) 01 (3.5) 00 (0.0) 07 ( 9.3) 0.31
Anti A4 03 (14.2) 04(14.2) 03 (17.6)  09 (12.0) 0.94
Anti A5 06 (28.5) 14 (50.0) 10 (58.8) 34 (45.3) 0.28
Anti A6 03 (14.2) 02 (7.1) 00 ( 0.0) 10 (13.3) 0.36
Anti A7 03 (14.2) 01 (3.5) 00 ( 0.0) 09 (12.0) 0.25
Anti B1 02 (9.5) 08 (28.5) 04 (23.5) 14 (18.6) 0.39
Anti B4 02 (9.5) 09 (32.1) 02 (11.7) 20 (26.6) 0.16
Anti B n.cat. ** 15 (71.4) 21 (75.0) 16 (94.1) 58 (77.3) 0.35
N - # of cases ** - not classified in categories
Table 2 - Prevalence of specific RSV antibodies: anti-A, anti-B and subtype-specific antibodies according to the viral status
detected in the sera of infants with LRTI.
RSV-specific Infection byRSV A N=86 Infection byRSV B N=24 RSV negativeN=75 P
antibodies N (%) N (%) N (%)
Anti-A* 71 (82.6) 20 (83.3) 67 (89.3) 0.88
Anti# A1 47 (54.7) 16 (66.7) 45 (60.0) 0.54
A2 69 (80.3) 20 (83.3) 66 (88.0) 0.41
A3 09 (10.5) 01 (4.2) 07 (9.3) 0.64
A4 12 (14.0) 05 (20.8) 09 (12.0) 0.56
A5 38 (44.2) 14 (58.3) 34 (45.3) 0.46
A6 10 (11.6) 02 (8.3) 10 (13.3) 0.80
A7 10 (11.6) 02 (8.3) 09 (12.0) 0.88
Anti-B* 65 (75.6) 21 (87.5) 58 (77.3) 0.33
Anti# B1 14 (16.3) 05 (20.8) 14 (18.7) 0.85
B4 15 (17.4) 04 (16.7) 20 (26.7) 0.31
Anti B not cat** 65 (5.6) 21 (87.5) 58 (77.3) 0.33
* Serum antibodies for RSV-specific type
# subtype-specific antibodies
** not classified in categories
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fants against LRTI related to those genotypes. The FI log
means for the anti-A2 antibody in infants infected with the
RSV genotype GA2 in comparison with the other genotypes
and also with the RSV(-) control group were similar (P =
0.98). Likewise, the means of the log FI of the anti-A5 an-
tibody in infants infected with RSV genotype GA5, in in-
fants infected with the other genotypes and in infants from
the RSV(-) group were similar (P = 0.73).
Poisson regression was applied to compare the number
of RSV subtype-specific antibodies in infants with LRTI due
to RSV A and RSV B, as well as in the RSV(-) group. The
mean numbers of anti-A subtype-specific antibodies for the
three groups were 2.24, 2.46 and 2.36, respectively, whereas
the mean numbers of anti-B subtype-specific antibodies
were 1.09, 1.25 and 1.19, respectively. Results were simi-
lar, regardless of the detection of the virus or RSV type.
All mothers presented specific antibodies against RSV
A and RSV B. Anti-A1 and anti-A2 antibodies were the
most prevalent. Infants presented a lower percentage of all
subtype-specific antibodies in comparison to their mothers.
However, the ratio of the prevalence in infants in relation
to the prevalence in mothers varied according to the dif-
ferent antibodies. There was a strong correlation between
the prevalence of each subtype-specific antibody in infants
and in their mothers (Spearman’s coefficient = 0.896, P =
0.001) (Figure 1).
DISCUSSION
The high rate of RSV isolates (61%) is similar to that
observed in infants during the RSV season in several coun-
tries.2-4 Infants admitted with severe RSV-LRTI presented
the usual clinical patterns characteristic of this population
– a few months in age and predominantly suffering from
bronchiolitis rather than bronchopneumonia (Table 1). 2, 21
RSV A was predominant, as verified in different regions
of the world. The predominant genotypes were A5, A2 and
B3, and these also represented the most frequently encoun-
tered in other regions of the world, such as in South Af-
rica, Uruguay and Argentina.22-24 The association of immun-
ofluorescence and culture for RSV rendered high sensitiv-
ity to the diagnostic method. Although the possibility ex-
ists of false negative results from our method which might
be identified by the use of RT-PCR, the known difference
in sensitivity between these methods does not suggest that
the interpretations of our results or the conclusions of this
study would be altered with the use of RT-PCR.25, 26
The serum antibody doses from the initial phase of the
disease reflect the contents of the serum prior to the acqui-
sition of infection. The results suggest that these antibod-
ies were acquired by passive transference because the pa-
tients’ ages (median of five months) and infection severity
are characteristic of a first contact with RSV21. Previous
seroprevalence studies have shown that anti-RSV maternal
antibodies remain in the infants’ blood during this specific
period of their lives, gradually decreasing until the sixth
to seventh month of life.8 An evaluation of antibodies dur-
ing the convalescence phase was not performed in this
study. This approach would certainly provide relevant in-
formation with regards to the infants’ response to infection.
The presence of subtype-specific antibodies for RSV A
and RSV B did not protect infants from RSV-related LRTI,
as shown by the high and similar seroprevalence of some
anti-A and anti-B antibodies in both the RSV(+) and RSV(-)
groups. Immunofluorescence was applied in these assess-
ments as it is considered a sensitive and specific assay suit-
able for detection of subtype-specific antibodies to RSV. 18
 The role of subtype-specific antibodies in protection
against LRTI caused by the corresponding genotype could
be evaluated only for the anti-A2 and anti-A5 antibodies.
The anti-A2 and anti-A5 antibodies did not protect against
LRTI caused by the RSV genotypes GA2 and GA5, respec-
tively. Seventy-one percent of infants infected with geno-
type GA2 presented the anti-A2 antibody, while 50% of
those infected with genotype GA5 presented the anti-A5
antibody. The prevalence of these two antibodies was also
similar in children infected with other genotypes and in
patients of the RSV (-) group (Table 2).
Although a high percentage of the infant samples pre-
sented the anti-A1 antibody, there was no infection caused
by this genotype, which could possibly suggest its protec-
tive effect. Nevertheless, seasonal variations of the geno-
type cannot be ruled out. In fact, the latter seems to ad-
equately explain the low prevalence of anti-A7 and anti-
Figure 1 - Prevalence of anti-RSV specific antibodies in the sera of infants
with LRTI and of their mothers.
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B4 antibodies in the sample without concomitantly elevated
prevalence of their corresponding genotypes.
All the facts mentioned above aid us in our understand-
ing the ethiopathogenesis of LRTI caused by RSV. At least
for infections caused by genotypes GA2 and GA5, the most
common in our sample, we were not able to confirm the hy-
pothesis that LRTI would be caused by genotypes against
which infants do not present specific serum immunity. There
is little information available about the role played by
subtype-specific antibodies in protecting infants from RSV
infections. McGill et al. examined maternal and infant im-
munity against subtype A lineages of RSV responsible for in-
fant infections in the United Kingdom.27 By using indirect
immunofluorescence and inoculation of the virus responsi-
ble for the infection, they found that infants, their mothers,
and uninfected children (control group) presented antibod-
ies specific to the genotype that caused the infection.27
Quantitative analysis of specific antibodies is very rel-
evant once large amounts of passively administered anti-
bodies (by intra-muscular or endovenous means) to
newborns and infants provide effective protection against
RSV-LRTI10,11. Additionally, groups with higher serum titers
of anti-RSV antibodies are better protected against LRTI,
as is the case observed for health care workers and older
children.21,27 Another finding in this study was that the quan-
tity of maternal antibodies was higher than in infants. Nev-
ertheless, this aspect was not fully explored because the
applied method was a semi-quantitative one that renders
quantification of this difference difficult. Quantitative as-
sessment of subtype-specific antibodies for RSV in infants
was limited by this method, and thus these results should
be interpreted with caution.18
Higher amounts of subtype-specific antibodies against
RSV, taking into account the natural variation encountered
in infants, did not provide protection against LRTI caused
by the corresponding viruses, as the means of the FI values
of the anti-A and anti-B antibodies were similar in the RSV
A, RSV B and RSV(-) groups. Additionally, the viral geno-
types GA2 and GA5 infected infants regardless of the FI of
the anti-A2 and anti-A5 antibodies (Table 6). In a different
analysis, no cut-off points were identified above which
subtype-specific anti-A2 and anti-A5 antibodies protected
against infection caused by the corresponding genotype.
One possible explanation for the absence of protection
attributed to higher amounts of specific antibodies would
be that the titers of specific antibodies naturally encoun-
tered in infants of few months in age are extremely low.
This fact may be corroborated by comparison with antibody
titers obtained with the use of monoclonal antibodies in
other studies. This comparison, however, is not feasible due
to diverse antibody quantification methods.
Altogether, the observed data suggest that serum-specific
anti-RSV antibodies, most probably maternally acquired, do
not fully protect infants from RSV-related LRTI. This con-
clusion is supported by strong clinical evidence since the peak
of RSV-related LRTI occurs in the first few months of life,
when the levels of maternal immunoglobulins are at their
highest. Unfortunately, confirmation of the hypothesis that
LRTI occurs due to the lack of subtype-specific antibodies
to fight the infecting genotype was compromised. It was also
not possible to clarify other confounding factors which may
potentially be involved in the pathophysiology of RSV-related
LRTI, such as airway immunity status, environmental pol-
lution, viral load and low socioeconomic levels of the fami-
lies.13,21,28,29
CONCLUSIONS
Type and subtype-specific serum antibodies encountered
naturally do not provide specific protection against LRTI
caused by RSV groups A or B or by the genotypes GA2,
GA5 and GB3 in infants. This finding was observed in spite
of the elevated seroprevalence of serum genotype-specific
antibodies against RSV. In order to corroborate these in-
teresting findings, these results should be re-examined in
other regions of the world, as well as for other genotypes
and subtype-specific antibodies.
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RESUMO
INTRODUÇÃO: O vírus sincicial respiratório é um dos
principais agentes etiológicos das infecções do aparelho
respiratório inferior em lactentes. Os genótipos deste vírus e
Vieira SE, Gilio AE, Durigon EL, B Ejzenberg. Infecção
por virus sincicial respiratório: o papel dos anticorpos
séricos específicos. Clinics. 2007; 62(6):709-16.
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o papel dos anticorpos séricos ainda não estão esclarecidos.
Este conhecimento é importante para o desenvolvimento de
medidas terapêuticas e profiláticas.
OBJETIVOS: Avaliar: os tipos e genótipos do vírus sincicial
que causam infecção respiratória em lactentes e a associação
dos anticorpos séricos subtipo-específicos com a ocorrência
de infecção; a presença de anticorpos subtipo-específicos nas
mães e sua associação com o perfil de anticorpos da criança.
MÉTODOS: Estudo prospectivo incluindo lactentes
hospitalizados com infecção respiratória. Foi coletada
secreção de nasofaringe para investigação viral usando
imunofluorescência indireta e cultivo viral. Foi coletado
sangue para pesquisa de anticorpos usando o sistema
Luminex Multiplex.
RESULTADOS: Avaliados 192 lactentes: 60,9% com vírus
sincicial (73,5% - A e 20,5% - B). Seis genótipos de vírus
sincicial respiratório foram identificados: A5,A2,B3,B5,A7
e B4. A soroprevalência dos anticorpos subtipos-específicos
foi alta. A presença e o nível de anticorpos subtipos-
específicos foram semelhantes, independentemente da
presença de infecção, tipo e genótipo do vírus. As mães e
as crianças apresentaram perfis semelhantes de anticorpos.
CONCLUSÕES: A prevalência dos anticorpos subtipos-
específicos foi elevada mas estes anticorpos não conferiram
proteção, independentemente do tipo/genótipo do vírus. A
semelhança dos perfis de anticorpos das mães e das crianças
foi compatível com transmissão transplacentária.
UNITERMOS: Respiratório. Sincicial. Anticorpo.
Imunidade. Crianças
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